Epigenetic Silencing of Tumor Suppressor miR-124 Directly Supports STAT3 Activation in Cutaneous T-Cell Lymphoma.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
15 12 2020
Historique:
received: 03 11 2020
revised: 03 12 2020
accepted: 07 12 2020
entrez: 18 12 2020
pubmed: 19 12 2020
medline: 22 6 2021
Statut: epublish

Résumé

Increasing evidence supports a potential role for STAT3 as a tumor driver in cutaneous T-cell lymphomas (CTCL). The mechanisms leading to STAT3 activation are not fully understood; however, we recently found that miR-124, a known STAT3 regulator, is robustly silenced in MF tumor-stage and CTCL cells. We studied here whether deregulation of miR-124 contributes to STAT3 pathway activation in CTCL. We measured the effect of ectopic mir-124 expression in active phosphorylated STAT3 (p-STAT3) levels and evaluated the transcriptional impact of miR-124-dependent STAT3 pathway regulation by expression microarray analysis. We found that ectopic expression of miR-124 results in massive downregulation of activated STAT3 in different CTCL lines, which resulted in a significant alteration of genetic signatures related with gene transcription and proliferation such as MYC and E2F. Our study highlights the importance of the miR-124/STAT3 axis in CTCL and demonstrates that the STAT3 pathway is regulated through epigenetic mechanisms in these cells. Since deregulated STAT3 signaling has a major impact on CTCL initiation and progression, a better understanding of the molecular basis of the miR-124/STAT3 axis may provide useful information for future personalized therapies.

Identifiants

pubmed: 33333886
pii: cells9122692
doi: 10.3390/cells9122692
pmc: PMC7765332
pii:
doi:

Substances chimiques

MIRN124 microRNA, human 0
MicroRNAs 0
STAT3 Transcription Factor 0
STAT3 protein, human 0
Janus Kinases EC 2.7.10.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Gastroenterology. 2000 Feb;118(2):356-67
pubmed: 10648464
Clin Cancer Res. 2016 Nov 1;22(21):5383-5393
pubmed: 27267853
Yale J Biol Med. 2020 Mar 27;93(1):111-121
pubmed: 32226341
Mol Cell. 2016 Sep 15;63(6):1089
pubmed: 27618489
Leukemia. 2001 May;15(5):787-93
pubmed: 11368440
Am J Hematol. 2009 Dec;84(12):821-5
pubmed: 19899130
Nat Genet. 2015 Dec;47(12):1465-70
pubmed: 26551667
Cytokine. 2014 Jan;65(1):17-23
pubmed: 24140069
Cancer Res. 2008 Apr 15;68(8):2689-98
pubmed: 18413736
Actas Dermosifiliogr. 2008 Apr;99(3):199-206
pubmed: 18358195
Oncol Lett. 2018 Nov;16(5):5875-5881
pubmed: 30344738
J Invest Dermatol. 2014 Oct;134(10):2639-2647
pubmed: 24756111
Cancers (Basel). 2019 Nov 02;11(11):
pubmed: 31684088
Am J Hematol. 2005 Sep;80(1):50-4
pubmed: 16138344
PLoS Biol. 2012;10(9):e1001395
pubmed: 23055831
Oncotarget. 2017 Oct 10;8(61):103775-103784
pubmed: 29262599
Cell Cycle. 2014;13(21):3331-5
pubmed: 25485578
Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):6086-6091
pubmed: 28533380
PLoS One. 2013 May 21;8(5):e63588
pubmed: 23704922
Oncol Rep. 2016 Mar;35(3):1385-94
pubmed: 26707908
Nucleic Acids Res. 2003 Feb 15;31(4):e15
pubmed: 12582260
Blood. 2011 Mar 24;117(12):3382-90
pubmed: 21252093
Leukemia. 2004 Jul;18(7):1288-95
pubmed: 15141228
Oncotarget. 2016 Mar 22;7(12):13563-74
pubmed: 26789110
Immunol Rev. 2018 Nov;286(1):148-159
pubmed: 30294965
Bioinformatics. 2004 Dec 12;20(18):3705-6
pubmed: 15297296
Mol Cell Biochem. 2014 Mar;388(1-2):219-31
pubmed: 24287565
Blood. 2016 Mar 10;127(10):1287-96
pubmed: 26738536
Haematologica. 2015 Nov;100(11):e450-3
pubmed: 26294736
Biochem Biophys Res Commun. 2013 Nov 29;441(4):873-9
pubmed: 24211205
Blood. 2019 Apr 18;133(16):1703-1714
pubmed: 30635287
Nat Genet. 2015 Dec;47(12):1426-34
pubmed: 26551670
Clin Cancer Res. 2016 Jul 1;22(13):3328-39
pubmed: 26851186
Nat Genet. 2015 Sep;47(9):1011-9
pubmed: 26192916
Mol Cancer. 2017 Mar 7;16(1):57
pubmed: 28270211
J Invest Dermatol. 2015 Apr;135(4):1128-1137
pubmed: 25405321
J Invest Dermatol. 2016 Jul;136(7):1490-1499
pubmed: 27039262
Protein Sci. 2018 Dec;27(12):1984-2009
pubmed: 30267440
Br J Dermatol. 2020 Jan;182(1):147-155
pubmed: 31049933
Curr Treat Options Oncol. 2016 Jul;17(7):33
pubmed: 27262707
Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6764-9
pubmed: 9192639
Cancer Res. 2015 Oct 1;75(19):4224-34
pubmed: 26238781
Science. 1997 Nov 28;278(5343):1612-5
pubmed: 9374458
J Invest Dermatol. 2015 Dec;135(12):3144-3152
pubmed: 26302069
J Invest Dermatol. 2011 Mar;131(3):762-8
pubmed: 21085192
J Invest Dermatol. 2008 Jul;128(7):1691-5
pubmed: 18200050
Oncoimmunology. 2017 Mar 17;6(5):e1306618
pubmed: 28638728
Toxicol Sci. 2018 Oct 1;165(2):462-474
pubmed: 29939353
Nat Genet. 2015 Sep;47(9):1056-60
pubmed: 26258847
Mol Cell Biol. 2008 Sep;28(17):5369-80
pubmed: 18591254
Blood. 2015 Jul 23;126(4):508-19
pubmed: 26082451
Blood. 2014 Mar 27;123(13):2034-43
pubmed: 24497536
Microb Pathog. 2019 Jun;131:65-74
pubmed: 30926417
J Invest Dermatol. 2012 Feb;132(2):440-7
pubmed: 21938013
J Invest Dermatol. 2018 Nov;138(11):2365-2376
pubmed: 29857068
Proc Natl Acad Sci U S A. 2014 Mar 11;111(10):3805-10
pubmed: 24567410
J Invest Dermatol. 2018 May;138(5):1022-1026
pubmed: 29681389
Nat Commun. 2015 Sep 29;6:8470
pubmed: 26415585
J Invest Dermatol. 2010 Feb;130(2):563-75
pubmed: 19710685

Auteurs

Lidia García-Colmenero (L)

Department of Dermatology, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma Barcelona, Carrer del Dr. Aiguader, 88, 08003 Barcelona, Spain.

Jéssica González (J)

Cancer Research Program Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.
Stem Cells and Cancer Research Laboratory-IMIM, CIBERONC, 08003 Barcelona, Spain.

Juan Sandoval (J)

Epigenomics Unit, IIS, La Fe, 46026 Valencia, Spain.

Yolanda Guillén (Y)

Stem Cells and Cancer Research Laboratory-IMIM, CIBERONC, 08003 Barcelona, Spain.

Angel Diaz-Lagares (A)

Cancer Epigenomics, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), CIBERONC, 15706 Santiago de Compostela, Spain.

Evelyn Andrades (E)

Department of Dermatology, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma Barcelona, Carrer del Dr. Aiguader, 88, 08003 Barcelona, Spain.
Cancer Research Program Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.

Arnau Iglesias (A)

Cancer Research Program Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.
Stem Cells and Cancer Research Laboratory-IMIM, CIBERONC, 08003 Barcelona, Spain.

Lara Nonell (L)

Microarray Department-IMIM, 08003 Barcelona, Spain.

Ramon Maria Pujol (RM)

Department of Dermatology, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma Barcelona, Carrer del Dr. Aiguader, 88, 08003 Barcelona, Spain.
Cancer Research Program Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.

Anna Bigas (A)

Stem Cells and Cancer Research Laboratory-IMIM, CIBERONC, 08003 Barcelona, Spain.

Lluís Espinosa (L)

Stem Cells and Cancer Research Laboratory-IMIM, CIBERONC, 08003 Barcelona, Spain.

Fernando Gallardo (F)

Department of Dermatology, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma Barcelona, Carrer del Dr. Aiguader, 88, 08003 Barcelona, Spain.
Cancer Research Program Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH